Cited by 406Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Disease and AdiposityCardiovascular Function and Risk Factors

Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis.

Eckel, Nathalie, Meidtner, Karina, Kalle-Uhlmann, Tamara, Stefan, Norbert, Schulze, Matthias B·2016·European Journal of Preventive Cardiology

Abstract

AIMS: Previous studies have provided inconsistent results about the cardiovascular risks for participants with metabolically healthy obesity (MHO). These uncertainties might partly reflect the lack of a uniform definition of MHO. We conducted a systematic review and meta-analysis to examine whether there is a suitable approach that identifies obese participants who are not at an increased risk of cardiovascular events compared with healthy normal-weight participants. METHODS AND RESULTS: Twenty-two prospective studies were eligible for the meta-analysis. Using random-effect models, pooled relative risks (RRs) were calculated for the combined effects of obesity with the presence or absence of metabolic syndrome, insulin resistance, hypertension, diabetes, hyperlipidaemia and any of these metabolic factors. Participants with MHO defined by the absence of metabolic syndrome were at increased risk for cardiovascular events compared with healthy normal-weight participants (pooled RR 1.45, 95% confidence interval (CI) 1.20-1.70), but had lower risks than unhealthy normal-weight (RR 2.07, 95% CI 1.62-2.65) and obese (RR 2.31, 95% CI 1.99-2.69) participants. The risk associated with participants who had MHO was particularly high over the long term. Similar risk estimates were observed when MHO was defined by other approaches. CONCLUSIONS: None of the approaches clearly identified an obese subgroup not at increased risk of cardiovascular events compared with normal-weight healthy participants. A benign obese phenotype might be defined by strict definitions, but insufficient studies exist to support this. More research is needed to better define MHO.

Integrity signals

Registry

Crossref · 10.1177/2047487315623884

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GLP-1 receptor agonists were historically approved exclusively to treat type 2 diabetes, but recent clinical trials concluded they are highly effective at weight management and cardiovascular disease prevention, leading to FDA approvals for these indications.

    “Historically, GLP-1 receptor agonists were exclusively approved to treat type 2 diabetes, but recent clinical trials concluded that they are highly effective at weight management and cardiovascular disease prevention, leading to US Food and Drug Administration (FDA) approvals for these indications.3”

Cites

Flagged first, then by citations

1 of the 64 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Eckel, N., Meidtner, K., Kalle-Uhlmann, T., Stefan, N., & Schulze, M. B.
Affiliations
  • German Center for Diabetes Research (DE)
  • German Institute of Human Nutrition (DE)
  • Helmholtz Munich (DE)
Corresponding author
Schulze, Matthias B
Venue
European Journal of Preventive Cardiology
Published
2016-06-01
Volume
23
Issue
9
Pages
956-966
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W2201485362
Cited by
405
References
64
Citations by year
2026: 26 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 52 · 2021: 52 · 2020: 44 · 2019: 38 · 2018: 37 · 2017: 24 · 2016: 6
FWCI
3.35
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Preventive Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Site cant be reached (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
metabolically healthy obesity, cardiovascular events, cardiovascular risk, metabolic syndrome, insulin resistance, hypertension, diabetes mellitus, hyperlipidemia, obesity phenotypes
MeSH terms
Obesity, Metabolically Benign, Cardiovascular Diseases, Humans, Phenotype, Prognosis, Risk Factors, Odds Ratio, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review